Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by PoorOpinionon Apr 16, 2018 10:54am
130 Views
Post# 27890623

RE:Commencing countdown, engines on

RE:Commencing countdown, engines on
FredTheVoice wrote:
Must reply to Candide. I dont think its a good idea to think and react that way....."well, nothing good for TH in the next 3 months....". Its a bad decision. Bad view of the potentiel of this company right now. And, I beleive that AT ANY MOMENT, this STOCK can leave for "far.......above the world".

I love this song by Bowie (Space oddity). I think strongly that those who logged out of TH after approval will soon see the spaceship gaining speed, and they will think : "well, I'm happy with my profits, but I must admit that I jumped out to early.....".

"Planet Earth is blue......and theres nothing I can do......"

My opinion.

FTV.



Fred is clearly floating above us, good luck with that.

I wanted to add that it's possible that Taimed might be our best source of info in the near-term.

We already know they shared most through the approval process and Theratech have an obligation to share commercialization info with them, there is a market Joint commmittee. Thera have to request shipments quarterly of the drug, at the very least Taimed need to be promptly informed of sales in order to ensure supplies are manufactured. I dont think there is any obligation for the two managements to have the same strategy on data release, we saw that thru the approval process. I'm hopeful more will come out from the Taimed side over the coming months.

BTW is the EU meeting this week? A PR could happen very quickly following that.


Bullboard Posts